Brief: GSK's Jemperli (Dostarlimab) Accepted For Review By Health Canada
24/09/2026 13:03
BRIEF-GSK's Jemperli (Dostarlimab) Accepted For Review By Health Canada Sept 24 (Reuters) - GSK plc GSK.L:
GSK'S JEMPERLI (DOSTARLIMAB) ACCEPTED FOR REVIEW BY HEALTH CANADA FOR PATIENTS WITH DMMR/MSI-H LOCALLY ADVANCED RECTAL CANCER
Source text: ID:nCNWz0RQRa
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))